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Abstract: Background Many studies have described the features of menstrually-related migraines (MRM)
in the natural cycle and the efficacy of prevention. MRM in combined hormonal contraceptive (CHC)
users has scarcely been researched. Estrogen and progestin withdrawal in CHC users are both more
abrupt and from higher hormone levels compared with the natural cycle. An advantage for prevention
of MRM in CHC users is that the hormone withdrawal is predictable. It is unknown, whether the
attacks during the hormone-free interval are associated with the hormone withdrawal or onset of bleeding.
Improved understanding of this relation might contribute to better define and shorten the time interval for
prevention. Methods For this prospective diary-based trial we collected migraine and bleeding data from
CHC users with MRM in at least two of three cycles. We analyzed frequency of migraines over the whole
CHC cycle. During the hormone-free phase the relation between onset of migraine and onset of bleeding
was studied. We compared pain intensity and identified prolonged-migraine attacks during hormone use
and the hormone-free phase. Results During the hormone-free interval the number of migraine days and
the pain score/migraine day were significantly higher in comparison with the mean during hormone use.
The prevalence of migraine attacks was fourfold on hormone-free days 3–6. Migraine typically started
on days 1–4. Migraine in relation to bleeding mostly occurred on days − 1 to + 4. In 78% of the cycles
the first migraine day occurred during bleeding days 1 ± 2 and 48% started on days − 1 and day 1.
The predictability of the first bleeding day was very high. Conclusion The day of hormone-withdrawal
migraine and the first bleeding day are highly predictable in CHC users. Migraine onset is mostly day −
1 and 1 of the bleeding and on days 1–4 of the hormone-free interval. Migraine attacks of CHC users in
the hormone-free interval are severe and long lasting. Further trials are necessary to investigate if this
knowledge can be used to optimise prevention.
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Abstract
Background: Many studies have described the features of menstrually-related migraines (MRM) in the natural
cycle and the efficacy of prevention. MRM in combined hormonal contraceptive (CHC) users has scarcely
been researched. Estrogen and progestin withdrawal in CHC users are both more abrupt and from higher
hormone levels compared with the natural cycle. An advantage for prevention of MRM in CHC users is that
the hormone withdrawal is predictable. It is unknown, whether the attacks during the hormone-free interval
are associated with the hormone withdrawal or onset of bleeding. Improved understanding of this relation
might contribute to better define and shorten the time interval for prevention.
Methods: For this prospective diary-based trial we collected migraine and bleeding data from CHC users with
MRM in at least two of three cycles. We analyzed frequency of migraines over the whole CHC cycle. During
the hormone-free phase the relation between onset of migraine and onset of bleeding was studied. We
compared pain intensity and identified prolonged-migraine attacks during hormone use and the hormone-
free phase.
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Results: During the hormone-free interval the number of migraine days and the pain score/migraine day
were significantly higher in comparison with the mean during hormone use. The prevalence of migraine
attacks was fourfold on hormone-free days 3–6. Migraine typically started on days 1–4. Migraine in relation to
bleeding mostly occurred on days − 1 to + 4. In 78% of the cycles the first migraine day occurred during
bleeding days 1 ± 2 and 48% started on days − 1 and day 1. The predictability of the first bleeding day was
very high.
Conclusion: The day of hormone-withdrawal migraine and the first bleeding day are highly predictable in
CHC users. Migraine onset is mostly day − 1 and 1 of the bleeding and on days 1–4 of the hormone-free
interval. Migraine attacks of CHC users in the hormone-free interval are severe and long lasting. Further trials
are necessary to investigate if this knowledge can be used to optimise prevention.
Keywords: Hormone, Estrogen withdrawal, Menstrual migraine, Menstrual bleeding, Contraception, Triptans,
Combined pill, Migraine prevention
Background
Migraine affects approximately 18% of women and is
ranked as the third most prevalent and seventh leading
cause of disability [1, 2]. Both incidence and prevalence
of migraine are 2–3 fold higher in women than in men
during the reproductive years and more than 50% of
women report an association between migraine and
menstruation [3, 4]. The International Classification of
Headache Disorders (ICHD-3) defines pure menstrual
migraine (PMM) as migraine occurring only on days 1 ±
2 of menstruation in at least two of three cycles and
menstrually-related migraine (MRM) if migraine also oc-
curs on other days of the cycle [5]. Estrogen withdrawal
is a recognised trigger for menstrual attacks in the nat-
ural cycle and in women using combined hormonal con-
traceptives (CHC) [6–8]. Estrogen-withdrawal headache
(EWH) is defined as a headache or migraine, which de-
velops within 5 days after daily consumption of exogen-
ous estrogen for three weeks or longer, which has been
interrupted. Prostaglandins released from the endomet-
rium during the phase of menstrual bleeding might also
play a key role in the pathophysiology of menstrual at-
tacks [9]. MRM attacks arecharacterized as more severe,
of longer duration and more resistant to treatment com-
pared to non-menstrual attacks [10–14]. With limited
options for successful acute treatment, the high burden
and the high prevalence of MRM demonstrate the need
for a better understanding of pathophysiology involved.
Many studies have described the features of PMM and
MRM in natural cycles and the efficacy of acute therapy
or short-term prevention over 5–7 days around the men-
strual bleeding [10, 12, 14–21]. In contrast, the course,
predictability and features of PMM and MRM in CHC
users have scarcely been researched, despite oral contra-
ception being used by more than 20% of women of re-
productive age in European countries [7, 22–24]. A
better understanding might allow more successful indi-
vidually tailored treatment of these headaches.
Estrogen and progestin withdrawal in CHC users are
more abrupt and follow higher estrogen levels compared
with withdrawal in the natural cycle. Currently, it is still
unknown if migraine during the hormone free interval
(HFI) in CHC users is associated with estrogen with-
drawal or with prostaglandin release associated with the
withdrawal bleed, or both. This is important for consid-
ering both type and timing of prevention, especially if
symptomatic treatment of menstrual attacks in CHC
users with MRM shows the same low response as it is
known from MRM in the natural cycle. The aim of this
prospectively conducted diary-based study was to iden-
tify the course and features of migraines in CHC users
diagnosed with menstrual migraine (MRM or PMM)
and to understand the temporal relationship between
onset of migraine in the HFI and the first day of bleed-
ing. We further analysed within woman variation in the
day of migraine onset and bleeding onset in the HFI
over several cycles.
Methods
This prospective trial was conducted at the Clinic for
Reproductive Endocrinology at the University Hospital
of Zurich, where one of the authors (GSM) runs a clinic
for hormonal migraine. Data were collected from
November 2017 to May 2019. Participants were re-
cruited at the clinic and through advertisement. We con-
tacted interested women by phone to explain the study
and clarify questions. We choose an observation period
of 3 cycles, as ICHD-3 recommends use of prospectively
conducted diaries over this period for research purposes
[5]. We checked whether their headaches during the
HFI were migraine and if they complied with the criteria
for inclusion. Women were included if they used CHC
(oral tablets, transdermal patches, or vaginal ring) in the
standard regimen of 21 days with a 7-day HFI, reported
migraine regularly occurring during the HFI in at least
two out of three cycles, experienced withdrawal
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bleeding, planned to continue the use of their CHC for
at least 3 more cycles, agreed to conduct daily diaries for
3 cycles and gave written informed consent. Exclusion
criteria comprised CHC use in flexible or extended cy-
cles, no CHC use, CHC use with shorter HFIs such as
24/4, and migraine during CHC use but not during the
HFI. After written consent was obtained, we collected
demographic data and a more detailed migraine history
during a semi-structured interview. Women who contin-
ued to fulfil the inclusion criteria were asked to
complete diaries for 3 cycles of a 21/7 CHC regimen (84
days). The diaries collected daily information on occur-
rence, intensity and duration of migraine attacks, use of
pain medication, CHC use and uterine bleeding. Pain in-
tensity was rated in the diaries according to a 4 point
scale (0 = no pain; 3 = severe pain). This score is easy to
understand and has been proven to be useful in daily
conducted diaries of migraineurs. As for the natural
cycle and in previous studies in CHC users it has been
found, that the long duration of MRM is a big burden,
we identified in addition to migraine days those migraine
attacks with a duration of more than 24 h. Diaries of
participants were excluded from the final data analyses,
if migraine was not reported in at least two of three cy-
cles. Furthermore, diaries from women who stopped
CHC use, withdraw consent or became pregnant were
excluded. The study has been approved by the regional
ethics committee (KEK-stV-Nr 2016–01791) and was
registered on clinicaltrials.gov: NCT04012593.
Statistical analyses
The programmes IBM SPSS Statistics 22 as well as Excel
2016 were used for statistical analyses. Baseline data are
given as mean (SD) or percent as appropriate. Mean
number of migraine days and days with pain medication
are given as mean (SD) per cycle and for each week of
the cycle for comparison with the HFI. To get more
insight into the occurrence of prolonged attacks we also
analysed the frequency of migraine attacks lasting longer
than 24 h. Pain scores are presented as the mean score/
migraine day for each week ofthe cycle. The number of
severe migraine attacks (score 3) is reported for week 1
and as the mean of weeks 2–4 (weekly number/ 3). Diar-
ies were started on the first day of pill use. To allow an
easier comparison with the natural cycle, which starts
with hormone withdrawal and bleeding we present our
data starting with the HFI and presented this as days 1–
7. Weeks two, three and four were the weeks with daily
CHC use. Parameters of interest were reported as daily
frequencies in percent and demonstrated as bar charts.
For the HFI interval and for bleeding days − 3 to 5 we
analysed in addition onset of migraine day and onset of
bleeding. This time interval is slightly longer than that
which is defined for MRM in the ICHD-3 classification
in order not to miss an association in this special group.
A similar procedure was used by MacGregor [11]. Daily
frequency for onset of bleeding during the defined inter-
vals was calculated. Comparisons of numeric data were
performed using chi-square test or Wilcoxon test as ap-
propriate. Relative risks for a migraine attack during pill
use in comparison to the risk during the HFI were calcu-
lated with Cochran-Mantel-Haenszel test.
Results
Of 68 women screened, 47 were eligible to participate
and 28 completed diaries over three cycles and contin-
ued to fulfil the inclusion criteria (Fig. 1). Altogether
complete diaries of 84 CHC cycles and 84 HFI were ana-
lysed. Mean age of the 28 women was 28 (±5.3) years,
height was 165 (±6) cm and weight was 59.4 (±12.9) kg.
Mean age at the first migraine attack was 18.0 (±6.1)
years, mean age at menarche was 13.1 ± 1.2 years. All
participants used low-dose CHC with an ethinylestradiol
dose ranging from 20 to 35 μg. Oral contraceptives were
used by 22 women whereas six women used the vaginal
ring. Most participants (96.5%) had never (68%) had
aura, or had experienced aura only once (28.5%). Only
3.5% reported in the interview to have had an aura more
than once. Many women (43%) stated that their mi-
graine was not relieved by symptomatic medication.
Sixty-four percent of the participants experienced
migraine during the HFI of all three cycles. One women
did not experience withdrawal bleeding in one of the
three HFI. Three of the 28 women were diagnosed with
PMM and the remainder had MRM. The mean number
of migraine days per 28-day cycle was 4.11 (±2.8), the
mean number of migraines lasting more than 24 h (epi-
sodes) was 0.5 (±0.7) and the mean number of days with
use of pain killers was 3.25 (±2.98). The mean pain
score/migraine day was1.92 (range1–3).. Of all migraine
attacks 104 were rated as severe (pain score 3) and 45%
of the latter occurred during the HFI. The mean dur-
ation of migraine attacks lasting more than 24 h was
56.78 (±34.27) hours. Table 1 demonstrates the parame-
ters of interest over the 28-days of the pill cycle and sep-
arate for each week [1–4]. During the HFI (presented as
week 1) the number of migraine days, migraine attacks
with a duration of more than 24 h, and consumed pain
medication, were significantly higher in comparison with
the weekly mean during hormone use. Also, the pain
score/migraines day was significantly higher. The relative
risk of having a migraine day on each day of the HFI in
comparison with the mean risk during CHC use was sig-
nificantly higher and fourfold for days 3–6 (Table 2).
Figure 2 demonstrates the percentage of migraine days
for each day of the pill cycle. Patients during the HFI
were most likely to experience migrainous headache on
day 4 (47.6%) followed by day 5 (40.4%) and days 3 and
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6 with 33.3% each. The rate declined and was much
lower one day after the first CHC intake (day 9).
The first migraine day during the HFI interval is of
interest to plan the initiation of short-term prevention.
Most migraines during the HFI started on days 1–4
(70.5%) (Fig. 3). In 58% of the cycles the first migraine
day of the HFI occurred on days 3–7 and in 37.8% on
days 4–7. The first bleeding day during the HFI oc-
curred in around 80% of the cycles on days 3 and 4 (Fig.
3). Migraine in relation to bleeding mostly occurred at
days − 1 to + 4 (Fig. 4a). We found that in 78% of the
cycles the first migraine day occurred during bleeding
days 1 ± 2, which is the period defined for the occur-
rence of menstrual migraine attacks. However, the typ-
ical start days of the menstrual attacks were day − 1 and
the first day of bleeding (48%). Only around 25% of at-
tacks started on bleeding days 2–5 (Fig. 4b). Migraine at-
tacks with a duration of more than 24 h were observed
in 45% of cycles, with 75% occurring during the HFI.
The mean duration of these attacks was 56.8 h.
The within-woman analysis showed that in 67% of the
women the first migraine day varied by not more than
Fig. 1 Flow chart of participants
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two days, and in 42% varied only by one day from cycle
to cycle (Fig. 5a). The first bleeding day was highly pre-
dictable with 42% of the participants always experiencing
bleeding starting on the same day of the HFI, and in
82% it was either the same day or one day later (Fig. 5b).
Discussion
In this prospective diary-based study in CHC users with
menstrual migraine diagnosed in accordance with ICHD
we found that most migraine days occurred during the
HFI (Fig. 2). The days with the highest attack frequency
(33% to 48%) were days 3–6 of the HFI. During these
days the relative risk of a migraine attack was fourfold in
comparison to days during CHC use (Table 1). The first
migraine day occurred with a frequency between 15%
and 19% on each of HFI days 1–4, very soon after hor-
mone withdrawal. The frequency declined to 5–8% on
HFI days 5–7 (Fig. 3). More relevant for the planning of
treatment is our analyses of the first migraine day in re-
lation to the first bleeding day, as we show, that this day
is highly predictable in most CHC users. Almost 50% of
attacks started on day − 1 and day 1 in relation to bleed-
ing and 78% started on the day first bleeding day ±2
days. These results are in line with the timing defined
for MRM in the ICHD. The incidence of migraine in
CHC users was highest on days − 1 to day 4, which dif-
fers from natural cycles, in which the highest incidence
of migraine is on days − 1 to 1 [25]. As for migraine
attacks associated with the natural cycle, we found that
menstrual attacks in CHC users were often rated as se-
vere [11, 14, 18, 19, 24, 26]. Three quarter of all attacks
were lasting longer than 24 h occurred during the HFI.
Those long attacks occurred although women used their
rescue medications as normal.
The distribution of migraine days over the HFI, the high
predictability of the first bleeding day and the observation
that migraine attacks start mostly on days − 1 to day + 4
in relation to the withdrawal bleed in CHC users confirm
the results of our pilot study [23]. In line with our data
Coffee et al. found that in 11 CHC users over 2 cycles the
typical start of bleeding was at days 3 and 4 [27]. Head-
ache scores in this trial were highest at days 3–7 of the
HFI, which is similar to the days of the HFI with highest
migraine prevalence in our study (days 3–6). The scores
were still slightly elevated during the first two days of pill
use, which is in line with our observation that migraine
prevalence remains slightly elevated during the first two
days of hormone restart, possibly due to the longer dur-
ation of attacks during the HFI. In the only trial of onset
of migraine in relation to the HFI days 2–5 were identified
as those with the highest prevalence of attacks in CHC
users [7]. This contrasts to our data, which include day 1
of the HFI. A direct comparison of the data with ours is
difficult as only women with PMM were included. An-
other trial comprised women with at least one migraine
attack per month. Here the authors report the prevalence
of migraine in CHC users in intervals of several days in re-
lation to the withdrawal bleeding [24]. Migraine preva-
lence was highest during bleeding days 1–3 (HR 2.18, 95%
CI 1.77–2.70), slightly elevated during the days − 2/− 1
(HR 1.32, 95% CI 1.01–1.72) and not significantly in-
creased on other days of the cycle. The authors did not re-
port onset of migraine days in relation to bleeding and
migraine frequency for each day of the HFI. In an interest-
ing recent retrospective cohort study oral contraceptive
users more commonly reported menstrually-related wors-
ening of headache in comparison to nonusers [28]. A limi-
tation of this trial is that the authors included women
with use of all types of oral contraception, including
Table 1 Migraine characteristics during the whole cycle and for each week of the cycle
Period Migraine days Days with pain medication Mean Pain score/
migraine day
(range 1–3)
Number of attacks with
a duration of 24 h
Complete cycle (28 Days) 4.11 ± 2.81 3.25 ± 2.98 1.92 0.45 ± 0.72
Number week 1 (hormone-free interval) 2.18 ± 1.59 1.61 ± 1.34 1.98 0.29 ± 0.53
Number week 2 (pill use) 0.7 ± 0.98 0.55 ± 0.94 1.74 0.05 ± 0.21
Number week 3 (pill use) 0.55 ± 0.96 0.50 ± 0.9 1.86 0.06 ± 0.21
Number week 4 (pill use) 0.68 ± 1.19 0.61 ± 1.2 1.74 0.06 ± 0.24
P-value week 1 vs mean of week 2–4 < 0.0001 < 0.0001 < 0.03 < 0.0001
Pain score 0–3: 0 = no pain; 3 = severe pain
Table 2 Relative risk for the occurrence of migraine on each
day of the hormone free interval compared to the pooled risk
of day 8–28
Relative risk Confidence interval
Day 1 2.286 0.992–5.269
Day 2 2.286 0.992–5.269
Day 3 4.000 1.850–8.648
Day 4 4.714 2.210–10.055
Day 5 4.857 2.282–10.336
Day 6 4.000 1.850–8.648
Day 7 2.857 1.276–6.396
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regimens without hormone-withdrawal. They did not re-
port how many women used progestin-only pills or com-
bined pills in a long-cycle regimen. Breakthrough bleeding
in such continuous regimen is rather a consequence of
hormone-induced changes of the endometrium than
hormone-withdrawal.
Short-term prevention for menstrual attacks in women
with PMM or MRM is recommended due to lack of effi-
cacy of acute treatment for these attacks with fewer than
30% responding to acute triptan treatment [29, 30].
Most authors recommend to start prevention two days
before the first expected headache day in the natural
cycle or on day 21 of pill intake in CHC users and to
continue for a period of 6–7 days [7, 16, 31, 32]. Adverse
events associated with daily use of triptans and the fact
that most migraineurs are likely to use additional trip-
tans during CHC use, raise the question if such a long
duration of prevention is necessary. Women with
Fig. 2 Migraine frequency for each day of the pill cycle
Fig. 3 Frequency of the first migraine day and the first bleeding day in the hormone-free interval
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additional nonmenstrual attacks might risk medication
overuse headache (MOH). In CHC users with the very
high predictability of the first bleeding day an individu-
ally tailored shorter time frame for prevention might be
the better option. Considering the high predictability of
the first bleeding day, the observation that in 50% of cy-
cles the first migraine day is day − 1 or + 1, and typically
within the range of days 1 ± 2 we suggest to start preven-
tion on bleeding day − 2 and continue for 3–4 days de-
pending on the typical duration of the attacks. The exact
interval of treatment could be individually adapted, if ne-
cessary based on diary data after two HFIs. The efficiacy
of such an approach needs to be investigated in future
trials. In one trial with a shortened HFI of 4 days use of
frovatriptan reduced headaches but was unexpectedly as-
sociated with delayed headache after the four HFI days
[33]. Preventing estrogen withdrawal with continuous/
extended cycle is another management option that has
been recommended for management of migraine during
the HFI [34]. While a continuous combined CHC regi-
men might prevent migraine during the HFI, it would in
contrast to use of the progestin-only pill with desoges-
trel, have no effect on migraine during hormone use.
Morotti et al. found in a comparative trial with desoges-
trel and an extended cycle CHC regimen only a signifi-
cant reduction in migraine days and pain medication in
desogestrel users [35]. Preliminary studies indicate con-
sistent, that switching to a progestin-only pill with deso-
gestrel is the better option, as MRM attacks and
nonmenstrual migraine attacks can be reduced. Further-
more use of this progestin is not associated with an in-
crease in cardiovascular risk or stroke [35–40].
Fig. 4 a /b: Migraine frequency and onset in relation to bleeding days day − 3 to day 5
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Strengths and limitations
The strengths of the current study include the prospect-
ive design with daily conducted diaries, the confirmed
diagnosis of migraine during an interview, the observa-
tion period of three complete cycles and the exclusion of
CHC users with other than the conventional 21/7 CHC
regimen. The within woman analyses of the first mi-
graine day during the HFI is of high relevance and dem-
onstrates how individual the reactions are with regard of
migraine onset, despite the same CHC regimen. The
study group consisted on women with mostly MRM and
only few non-menstrual related migraine attacks. There-
fore the comparison of the number of prolonged attacks
between the HFI with weeks 2–4 has to be interpreted
with caution. The strict inclusion criteria impeded re-
cruitment and despite our interesting results, it must be
acknowledged that this study was performed on a small
number of subjects.
Conclusion
Migraine attacks of CHC users are frequently severe and
long lasting in the HFI. The highest prevalence of mi-
graine was on days − 1 to 4 in relation to bleeding. The
day of hormone-withdrawal migraine and the first bleed-
ing day are highly predictable in CHC users. Migraine
onset is mostly at day − 1 and 1 of the bleeding and on
days 1–4 of the HFI. Further trials are necessary to in-
vestigate if this knowledge can be used to shorten and
individualise the duration of prevention in CHC users.
More research is needed to understand the pathophysi-
ology of migraine during the HFI in CHC users with
particular regard to estrogen withdrawal and/or uterine
bleeding, and to optimize treatment.
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